Corbus Pharmaceuticals Holdings, Inc. (CRBP): who owns it and who trades it
As of Nov 16, 2026, CRBP insiders reported 14 open-market sales worth $2.7M and 3 purchases worth $126K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Cormorant Asset Management, LP (Other), with $1.7M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Corbus Pharmaceuticals Holdings
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CRBP
108 funds and institutions reported CRBP shares worth $130M at the end of Q2 2026, about 78% of the company. The largest holder is Cormorant Asset Management, LP with 13.2%.
Funds and institutions (13F) 78%Everyone else 22%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 2.34M | 13.22% | $22M | No change |
| Orbimed Advisors LLC | 1.74M | 9.80% | $16.3M | No change |
| BlackRock, Inc. | 1.33M | 7.51% | $12.5M | +390% |
| Aberdeen Group plc | 1.32M | 7.45% | $12.4M | No change |
| Vanguard Capital Management LLC | 760,940 | 4.29% | $7.1M | +4% |
| Jones Hill Capital LP | 653,572 | 3.68% | $6.1M | – |
| Prosight Management, LP | 650,000 | 3.66% | $6.1M | -7% |
| Stonepine Capital Management, LLC | 425,000 | 2.40% | $4M | +11% |
| Geode Capital Management, LLC | 423,374 | 2.39% | $4M | +126% |
| ADAR1 Capital Management, LLC | 421,787 | 2.38% | $4M | +27% |
| Diadema Partners LP | 301,264 | 1.70% | $2.8M | -32% |
| Susquehanna International Group, LLP | 293,203 | 1.65% | $2.8M | -12% |
| State Street Corp | 254,672 | 1.44% | $2.4M | +270% |
| Dimensional Fund Advisors LP | 190,214 | 1.07% | $1.8M | +39% |
| Exome Asset Management LLC | 184,914 | 1.04% | $1.7M | -21% |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 151,640 | 0.85% | $1.4M | -5% |
| Jane Street Group, LLC | 139,133 | 0.78% | $1.3M | +90% |
| Northern Trust Corp | 124,906 | 0.70% | $1.2M | +201% |
| Vanguard Fiduciary Trust Co | 112,397 | 0.63% | $1.1M | +17% |
| Vanguard Portfolio Management LLC | 111,302 | 0.63% | $1M | +357% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CRBP insiders reported $126K of open-market purchases and $2.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Cormorant Asset Management, LP +2 | Other | Sale | 425,000 | $4.10 | $1.7M | Form 4 |
| Sep 14, 2026 | Yong Ben | Director | Sale | 2,000 | $7.84 | $15.7K | Form 4 |
| Aug 11, 2026 | Nishant C Saxena | Chief Business Officer | Purchase | 2,600 | $9.63 | $25K | Form 4 |
| Aug 7, 2026 | Yuval Cohen | CEO | Sale | 17,000 | $10.08 | $171K | Form 4 |
| Aug 7, 2026 | Sean F. Moran | CFO | Sale | 12,000 | $10.08 | $121K | Form 4 |
| Jun 10, 2026 | Winston Kung | Director | Sale | 2,026 | $7.91 | $16K | Form 4 |
| Jun 10, 2026 | John Kenneth Jenkins | Director | Sale | 4,800 | $7.91 | $38K | Form 4 |
| Jun 10, 2026 | Anne Altmeyer | Director | Sale | 2,412 | $7.91 | $19.1K | Form 4 |
| Jun 3, 2026 | Nishant C Saxena | Chief Business Officer | Purchase | 9,000 | $7.58 | $68.2K | Form 4 |
| Jun 2, 2026 | Nishant C Saxena | Chief Business Officer | Purchase | 4,500 | $7.33 | $33K | Form 4 |
| Mar 2, 2026 | Dominic Smethurst | Chief Medical Officer | Sale | 6,097 | $8.30 | $50.6K | Form 4 |
| Feb 17, 2026 | Ian Hodgson | Chief Operating Officer | Sale | 847 | $7.38 | $6.3K | Form 4 |
| Feb 13, 2026 | Sean F. Moran | CFO | Sale | 4,701 | $7.78 | $36.6K | Form 4 |
| Feb 13, 2026 | Yuval Cohen | CEO | Sale | 13,871 | $7.78 | $108K | Form 4 |
| Feb 3, 2026 | Dominic Smethurst | Chief Medical Officer | Sale | 3,285 | $8.09 | $26.6K | Form 4 |
| Feb 3, 2026 | Ian Hodgson | Chief Operating Officer | Sale | 2,415 | $8.09 | $19.5K | Form 4 |
| Dec 11, 2025 | Bihua Chen +2 | 10% owner | Sale | 30,029 | $11.46 | $344K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Cormorant Asset Management, LP | Other | – | $1.7M | Oct 29, 2026 |
| Bihua Chen | 10% owner | – | $344K | Dec 11, 2025 |
| Yuval Cohen | Chief Executive Officer, Director | – | $279K | Aug 7, 2026 |
| Sean F. Moran | Chief Financial Officer | – | $158K | Aug 7, 2026 |
| Nishant C Saxena | Chief Business Officer | $126K | – | Aug 11, 2026 |
| Dominic Smethurst | Chief Medical Officer | – | $77.2K | Mar 2, 2026 |
| John Kenneth Jenkins | Director | – | $38K | Jun 10, 2026 |
| Ian Hodgson | Chief Operating Officer | – | $25.8K | Feb 17, 2026 |
| Anne Altmeyer | Director | – | $19.1K | Jun 10, 2026 |
| Winston Kung | Director | – | $16K | Jun 10, 2026 |
| Yong Ben | Director | – | $15.7K | Sep 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CRBP short interest
High short interest. 16.8% of CRBP shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 171%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.24M CRBP shares were sold short, 16.8% of the shares outstanding, up 19.5% from the report before. At the average daily volume of 933,143 shares, buying them all back would take about 3.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.24M | 16.77% | +20% | 933,143 | 3.5 |
| Oct 15, 2026 | 2.71M | 14.03% | -11% | 958,765 | 2.8 |
| Sep 30, 2026 | 3.05M | 15.80% | +11% | 791,386 | 3.9 |
| Sep 15, 2026 | 2.76M | 14.27% | +23% | 1.79M | 1.5 |
| Aug 31, 2026 | 2.25M | 11.61% | +5% | 611,617 | 3.7 |
| Aug 14, 2026 | 2.15M | 11.10% | -7% | 355,454 | 6.0 |
| Jul 31, 2026 | 2.30M | 12.96% | +10% | 245,178 | 9.4 |
| Jul 15, 2026 | 2.10M | 11.82% | +8% | 355,484 | 5.9 |
| Jun 30, 2026 | 1.95M | 10.97% | +23% | 571,496 | 3.4 |
| Jun 15, 2026 | 1.58M | 8.91% | +3% | 465,281 | 3.4 |
| May 29, 2026 | 1.53M | 8.62% | +28% | 1.07M | 1.4 |
| May 15, 2026 | 1.20M | 6.74% | -15% | 306,697 | 3.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Corbus Pharmaceuticals Holdings company events
Corbus Pharmaceuticals Holdings filed 17 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Oct 15, 2026AnnouncementShared information with investors. Filing
- Sep 14, 2026AnnouncementThe Company announced positive topline data from the CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 6, 2026AgreementCorbus Pharmaceuticals Holdings, Inc. entered into an employment agreement with Leonardo Viana Nicacio, MD, effective August 3, 2026, and will be effective for a period of two (2) years from the date thereof. Filing
- May 26, 2026AnnouncementThe Company announced updated data from its Phase 1/2 clinical study of CRB-701 (SYS6002), a next-generation Nectin-4 targeted ADC. The new data demonstrate robust activity in the second line (2L) setting of two solid tumor types that express high levels of Nectin-4 and are primarily driven by… Filing
- May 21, 2026LeadershipThe Compensation Committee granted Brent Pfeiffenberger the following initial equity awards under the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Incentive Plan in connection with his appointment to the Board: (i) a nonqualified stock option to purchase 24,700 shares of the Company’s common… Filing
- May 14, 2026LeadershipThe board of directors of Corbus Pharmaceuticals Holdings, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Brent Pfeiffenberger, age 48, to serve as a member of the Board, thereby expanding the Board to seven members. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 16, 2026LeadershipCorbus Pharmaceuticals Holdings, Inc. entered into amended and restated employment agreements, effective April 15, 2026, with certain of the Company’s executive officers: Yuval Cohen, Ph.D., Chief Executive Officer and Sean Moran, Chief Financial Officer. Filing
- Apr 14, 2026AnnouncementThe Company announced Last Patient First Visit in the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. Filing
- Apr 7, 2026LeadershipCorbus Pharmaceuticals Holdings, Inc. was notified by Dominic Smethurst, the Company’s Chief Medical Officer, of his resignation, effective June 30, 2026. Filing
- Mar 9, 2026ResultsReleased financial results. Filing
- Feb 25, 2026AnnouncementShared information with investors. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Dec 18, 2025LeadershipAlan Holmer provided Corbus Pharmaceuticals Holdings, Inc. with notice of his resignation from the Board of Directors, effective December 31, 2025, due to retirement. Filing
- Dec 11, 2025AnnouncementThe Company announced the completion of the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study, with completion expected in summer 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Corbus Pharmaceuticals Holdings financials
Famous investors that hold CRBP
3 of the 50 well-known investors we track reported holding CRBP in their latest 13F filing. The largest position is Jim Simons's, worth $647K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 94,900 | $647K | 0.0% | -14% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 89,312 | $609K | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 81,269 | $554K | 0.0% | +611% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named CRBP in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | MPM BioImpact LLC | 13G | 8.6% |
| Nov 13, 2026 | MPM BioImpact LLC | 13G | 8.6% |
| Nov 2, 2026 | Cormorant Asset Management, LP | 13G/A | 7.8% |
| Nov 2, 2026 | Cormorant Asset Management, LP | 13G/A | 7.8% |
| Oct 29, 2026 | Aberdeen Group plc | 13G/A | 0.0% |
| Oct 29, 2026 | Aberdeen Group plc | 13G/A | 0.0% |
Questions about Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock
Who owns the most CRBP stock?
The largest reported owner of Corbus Pharmaceuticals Holdings, Inc. (CRBP) is Cormorant Asset Management, LP, with 13.2% of the company. In total, 108 funds and institutions reported holding CRBP at the end of Q2 2026, together about 78% of the shares. See the largest owners.
Are CRBP insiders buying or selling?
In the last 12 months, CRBP insiders reported 3 open-market purchases worth $126K and 14 sales worth $2.7M. The latest trade was on Oct 29, 2026. See every trade.
What is the short interest in CRBP?
As of Oct 30, 2026, 3.24M CRBP shares were sold short, 16.8% of the shares outstanding, up 19.5% from the report before. At the average daily volume of 933,143 shares, buying them all back would take about 3.5 trading days (days to cover). See the history.
Which famous investors hold CRBP?
3 of the 50 well-known investors we track reported CRBP in their latest 13F filing, including Jim Simons, Steve Cohen, Israel Englander. The largest position is worth $647K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.